Advertisement
Home Day 4

Day 4

video

The Future of BCMA-Targeting in Myeloma

Noopur Raje, MD, director of the multiple myeloma program at Massachusetts General Hospital, looks into the future of BCMA-targeting CAR T-cell therapies...

Ibrutinib Plus Ianalumab Shows Promising Results in Early-Phase Trial

According to findings from a dose-escalation/expansion trial presented at the 2021 ASH Annual Meeting, adding ianalumab to ibrutinib was well-tolerated, with clinical...

Peripheral Blood Cytopenias Could Represent an Early Marker of Cancer Mortality Risk

Peripheral blood cytopenia is a persistent clinical challenge and, according to findings from the REGARDS trial, it may be associated with a...

Older Patients With Newly Diagnosed CLL Benefit From Frontline Targeted Treatment

Although individuals older than 80 years make up more than 20% of cases of chronic lymphocytic leukemia (CLL), this population is underrepresented...

GLOW: MRD Outcomes After Fixed-Duration Ibrutinib Combinations in Older CLL Patients

The all-oral, once-daily, fixed-duration combination of ibrutinib and venetoclax demonstrated superior undetectable MRD responses in older or unfit patients with previously untreated...
Advertisement
Advertisement